OrPro Therapeutics is developing ORP100S, a novel biologic therapy to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection. ORP100S is delivered via inhalation and is planned for home use with the objective of filling a key gap in COVID-19 treatment not addressed by vaccines, antivirals and late-stage therapies by reducing disease severity and the need for hospitalization.